美泊利单抗在嗜酸性粒细胞增多疾病的治疗进展
Advances in the treatment of eosinophilia related diseases with mepolizumab
张学兰 1叶小萌 1赵健 1孟静1
作者信息
- 1. 武警安徽省总队医院呼吸内科,安徽合肥 230041
- 折叠
摘要
嗜酸性粒细胞增多相关疾病较多,其病因不同,治疗方案也不相同,非感染和非肿瘤嗜酸性粒细胞增多相关疾病的一线治疗大多为糖皮质激素,根据病情轻重可联合免疫抑制剂治疗.美泊利单抗(mepolizumab)是一种人源抗白介素-5单克隆抗体,目前已被美国FDA批准用于慢性鼻-鼻窦炎伴鼻息肉(Chronic sinusitis with nasal polyps)、嗜酸性肉芽肿多血管炎(eosinophilic granulomatosis with polyangiitis)及高嗜酸性粒细胞综合征(hypereosinophilic syndrome)的二线治疗.现就美泊利单抗治疗除支气管哮喘(bronchial asthma)外相关嗜酸性粒细胞的应用研究进展作综述.
Abstract
There are many eosinophilia-related diseases,with different etiologies and different therapeutic programs.The first-line treatment for non-infectious and non-tumor-related eosinophilia-related diseases is mostly glucocorticoids,which can be combined with immunosuppressive agents according to the severity of the disease.Mepolizumab is a human anti-interleukin-5 monoclonal antibody which has been approved by the FDA for second-line treatment for chronic sinusitis with nasal polyps,eosinophilic granulomatosis with polyangiitis,and hypereosinophilic syndrome.This article reviewed the research progress of mepolizumab in the application of eosinophilia-related diseases except bronchial asthma.
关键词
嗜酸性粒细胞增多/美泊利珠单抗/临床应用Key words
eosinophilia/mepolizumab/clinical application引用本文复制引用
出版年
2024
NETL
NSTL
万方数据